Photo of Marlise R. Luskin,  MD, MSCE

Marlise R. Luskin, MD, MSCE

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute


Marlise_Luskin@dfci.harvard.edu

Marlise R. Luskin, MD, MSCE

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Instructor, Medicine, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a member of the Adult Leukemia Program at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. My primary research interest is conducting clinical trials of novel agents for acute leukemias and related blood cancers (myelodysplastic syndromes and myeloproliferative neoplasms). I also have an interest in conducting clinical epidemiology and outcomes research for patients with these diseases. I earned a Master’s of Science in Clinical Epidemiology (MSCE) during my fellowship (2012-2015) at the University of Pennsylvania which provided important foundation in clinical trials and clinical epidemiology research. This program included coursework in biostatistics, epidemiology, research methodology, clinical trial design, and database management, as well as an independent thesis project. My thesis investigated the prognostic ability of a novel methylation-based biomarker (M-score) in de novo AML. This research showed that a classifier based on the M-score is excellent at identifying AML subgroups with differing clinical outcome. I confirmed the performance of the M-score classifier in key AML subgroups and in an independent cohort of patients enrolled in a ECOG study (JCI Insight 2016). In addition to my thesis, I have completed several other epidemiologic studies including one study that identified an association of mutated NPM1 with the development of leukemia cutis (Haematologica 2015) and another showing that high-risk AML subgroups (including patients with FLT3-ITD) benefit from high-dose daunorubicin induction (Blood 2016). More recently, I completed a project showing that poor sleep is associated with inferior outcomes in MDS (British Journal of Hematology 2016). I have also been involved in the design and completion of several therapeutic trial. While a fellow at the University of Pennsylvania, I wrote a pilot/phase I trial to evaluate the feasibility, safety, and efficacy of adding interferon-α to donor lymphocyte infusion for treatment of patients with relapsed acute leukemia after allogeneic stem cell transplantation. After joining the faculty at DFCI, I completed the Methods in Clinical Research Course designed to provide intensive training to PIs conducting trials at DFCI. Since completing that course, I have assumed the role as site PI for multiple for acute leukemia at DFCI. I am the PI for a CTEP-sponsored study of blinatumomab in combination with checkpoint blockade for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) as well as an industry-sponsored study of a HSP90 inhibitor for relapse/refractory FLT3-ITD mutant AML. I have also personally written and obtained FDA, industry, and IRB approval for an IST which will soon open investigating a novel TKI in the initial treatment of BCR-ABL+ B-cell ALL: Phase 1 study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive B-cell acute lymphoblastic leukemia (BCR-ABL+ B-ALL) and chronic myeloid leukemia (CML).

Publications

Powered by Harvard Catalyst
  • Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867-879. PubMed
  • Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study. Haematologica 2019. PubMed
  • Stern RM, Luskin MR, Clark RP, Miller AL, Loscalzo J. A Headache of a Diagnosis. N Engl J Med 2018; 379:475-479. PubMed
  • Luskin MR, Murakami MA, Manalis SR, Weinstock DM. Targeting minimal residual disease: a path to cure? Nat Rev Cancer 2018; 18:255-263. PubMed
  • Luskin MR, DeAngelo DJ. How to treat chronic myeloid leukemia (CML) in older adults. 2018. PubMed
  • Luskin MR. Chronic myeloid leukemia and pregnancy: patient and partner perspectives. Expert Rev Hematol 2019; 11:597-599. PubMed
  • Luskin MR, Abel GA. Management of older adults with myelodysplastic syndromes (MDS). 2018. PubMed
  • Luskin MR, DeAngelo DJ. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol 2017; 10:1033-1045. PubMed
  • Luskin MR, Discenza MN, Easter SR, Dal Cin P, Owen R, Ilagan B, Masiello M, Lane AA. Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv 2018; 1:1491-1494. PubMed
  • Luskin MR, Stone RM. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? J Oncol Pract 2017; 13:471-480. PubMed
  • Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients age 70 years and older in the United States. Blood 2017. PubMed
  • Luskin MR, DeAngelo DJ. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Curr Hematol Malig Rep 2017. PubMed
  • Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology 2017. PubMed
  • Dinardo CD, Luskin MR, Carroll M, Smith C, Harrison J, Pierce S, Kornblau S, Konopleva M, Kadia T, Kantarjian H, Wertheim GB, Master SR. Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML. Am J Hematol 2018; 92:E14-E15. PubMed
  • Honigberg MC, Eshel N, Luskin MR, Shaykevich S, Lipsitz SR, Katz JT. Curricular Time, Patient Exposure, and Comfort Caring for Lesbian, Gay, Bisexual, and Transgender Patients Among Recent Medical Graduates. LGBT Health 2018; 4:237-239. PubMed
  • Banerjee R, Luskin MR, Loren AW. Late effects of blood and marrow transplantation. Haematologica 2019; 102:e465. PubMed
  • Wertheim GBW, Luskin MR, Carroll M, Master SR. Microsphere-Based Assessment of DNA Methylation for AML Prognosis. Methods Mol Biol 2018; 1633:125-136. PubMed
  • Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 2018. PubMed
  • Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2018; 127:1551-8. PubMed
  • Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. British Journal of Haematology 2018; 174:332-4. PubMed
  • Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018; 22:1961-1967. PubMed
  • Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE 2019; 11:e0153016. PubMed
  • Aikawa V, Porter D, Luskin MR, Bagg A, Morrissette JJ. Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genet 2015; 208:625-9. PubMed
  • Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE. NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica 2018; 100:e412-4. PubMed
  • Luskin MR, Banerjee R, Del Percio S, Loren AW. A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. Curr Hematol Malig Rep 2018; 10:225-36. PubMed
  • Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL. High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J Clin Oncol 2018; 33:2392-8. PubMed
  • Tsai DE, Luskin MR, Kremer BE, Chung AK, Arnoldi S, Paralkar VR, Nasta SD, Stadtmauer EA, Schuster SJ, Xavier M. A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types. Leuk Lymphoma 2019; 56:1530-2. PubMed
  • Frosch Z, Luskin MR, Landsburg DJ, Schuster SJ, Svoboda J, Loren AW, Porter DL, Stadtmauer EA, Nasta SD. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2015; 15:92-7. PubMed
  • Wertheim GB, Smith C, Luskin M, Rager A, Figueroa ME, Carroll M, Master SR. Validation of DNA methylation to predict outcome in acute myeloid leukemia by use of xMELP. Clin Chem 2019; 61:249-58. PubMed
  • Luskin M, Wertheim G, Morrissette J, Daber R, Biegel J, Wilmoth D, Kersun L, King R, Paessler M, Simon C, Aplenc R, Loren A. CLL/SLL diagnosed in an adolescent. Pediatr Blood Cancer 2015; 61:1107-10. PubMed
  • Luskin MR, Roy DB, Wasik MA, Loren AW. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen. Clin Lymphoma Myeloma Leuk 2015; 14:e55-8. PubMed
  • Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011; 9:1209-16. PubMed
  • Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT, Kottilil S, Lifson JD, Metcalf JA, Lempicki RA, Connors M. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol 2018; 82:3997-4006. PubMed
  • Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT, Connors M. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J Virol 2018; 81:2713-25. PubMed
  • Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2018; 80:11486-97. PubMed
  • Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2009; 37:248-51. PubMed
Hide
Member Summary Video